Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Сен. 18, 2024
The
glucagon-like
peptide-1
(GLP-1)
receptor,
known
as
GLP-1R,
is
a
vital
component
of
the
G
protein-coupled
receptor
(GPCR)
family
and
found
primarily
on
surfaces
various
cell
types
within
human
body.
This
specifically
interacts
with
GLP-1,
key
hormone
that
plays
an
integral
role
in
regulating
blood
glucose
levels,
lipid
metabolism,
several
other
crucial
biological
functions.
In
recent
years,
GLP-1
medications
have
become
focal
point
medical
community
due
to
their
innovative
treatment
mechanisms,
significant
therapeutic
efficacy,
broad
development
prospects.
article
thoroughly
traces
developmental
milestones
drugs,
from
initial
discovery
clinical
application,
detailing
evolution
diverse
along
distinct
pharmacological
properties.
Additionally,
this
paper
explores
potential
applications
agonists
(GLP-1RAs)
fields
such
neuroprotection,
anti-infection
measures,
reduction
inflammation,
enhancement
cardiovascular
function.
It
provides
in-depth
assessment
effectiveness
GLP-1RAs
across
multiple
body
systems-including
nervous,
cardiovascular,
musculoskeletal,
digestive
systems.
includes
integrating
latest
trial
data
delving
into
signaling
pathways
mechanisms.
primary
goal
emphasize
extensive
benefits
using
treating
spectrum
diseases,
obesity,
non-alcoholic
fatty
liver
disease
(NAFLD),
neurodegenerative
musculoskeletal
forms
cancer.
ongoing
new
indications
for
drugs
offers
promising
prospects
further
expanding
interventions,
showcasing
field.
Язык: Английский
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Biomedicines,
Год журнала:
2024,
Номер
12(8), С. 1630 - 1630
Опубликована: Июль 23, 2024
Diabetes
mellitus
(DM)
and
osteoarthritis
(OA)
are
prevalent
chronic
conditions
with
shared
pathophysiological
links,
including
inflammation
metabolic
dysregulation.
This
study
investigates
the
potential
impact
of
insulin,
metformin,
GLP-1-based
therapies
on
OA
progression.
Methods
involved
a
literature
review
clinical
trials
mechanistic
studies
exploring
effects
these
medications
outcomes.
Results
indicate
that
beyond
its
role
in
glycemic
control,
may
modulate
inflammatory
pathways
relevant
to
OA,
potentially
influencing
joint
health.
Metformin,
recognized
for
anti-inflammatory
properties
via
AMPK
activation,
shows
promise
mitigating
progression
by
preserving
cartilage
integrity
reducing
markers.
therapies,
known
enhancing
insulin
secretion
improving
profiles
DM,
also
exhibit
benefit
suppressing
cytokine-mediated
supporting
repair
mechanisms.
Conclusions
suggest
medications,
while
primarily
indicated
diabetes
management,
hold
therapeutic
targeting
common
underlying
Further
warranted
validate
findings
explore
optimal
strategies
managing
both
DM
comorbidities
effectively.
Язык: Английский
Advances in GLP-1 receptor agonists for pain treatment and their future potential
The Journal of Headache and Pain,
Год журнала:
2025,
Номер
26(1)
Опубликована: Фев. 27, 2025
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs)
show
substantial
efficacy
in
regulating
blood
glucose
levels
and
lipid
metabolism,
initially
as
an
effective
treatment
for
diabetes
mellitus.
In
recent
years,
GLP-1RAs
have
become
a
focal
point
the
medical
community
due
to
their
innovative
mechanisms,
robust
therapeutic
efficacy,
expansive
development
prospects.
Notably,
benefit
pain
management
through
neuroprotective
metabolic
regulatory
properties,
such
inhibiting
inflammation
responses
oxidative
stress,
promoting
β-endorphin
release
modulating
several
other
crucial
biological
pathways.
Hence
hold
promise
repurposing
treatments
disorders.
this
narrative
review,
we
thoroughly
trace
current
preclinical
clinical
evidence
of
seven
modalities,
including
inflammatory
pain,
osteoarthritis,
visceral
neuropathic
diabetic
neuropathy,
cancer
headache,
support
underlying
mechanisms
agents
suffering.
Despite
these
promising
findings,
further
research
is
necessary
establish
long-term
optimal
dosing
strategies,
potential
synergistic
interactions
with
existing
therapies.
Future
trials
should
aim
distinguish
direct
analgesic
effects
from
benefits
explore
broader
applications
conditions.
The
ongoing
exploration
new
indications
highlights
transformative
advancing
across
diverse
fields.
Язык: Английский
GLP-1R agonist therapy and vaccine response: Neglected implications
Cytokine & Growth Factor Reviews,
Год журнала:
2024,
Номер
78, С. 14 - 24
Опубликована: Июль 15, 2024
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs),
such
as
semaglutide
(Ozempic®),
have
emerged
effective
treatments
for
diabetes
and
weight
management.
However,
recent
evidence
indicates
that
GLP-1R
signalling
influences
various
tissues,
including
the
immune
system.
Notably,
GLP-1
has
a
short
half-life
(<
5
minutes)
exists
in
picomolar
range,
while
GLP-1RAs
like
extended
half-lives
of
several
days
are
administered
at
supraphysiological
doses.
This
review
explores
potential
impact
these
medications
on
vaccine
efficacy.
We
examine
suggesting
may
attenuate
responses
through
direct
effects
cells
modulation
other
tissues.
Additionally,
we
discuss
how
create
tolerogenic
environment,
potentially
reducing
immunogenicity.
Given
widespread
use
GLP-1RAs,
it
is
crucial
to
understand
their
translational
implications
vaccination
outcomes.
Язык: Английский